TT-P34 Phase 1 Trial Shows CNS Exposure in Parkinson’s

Teitur Trophics’ first-in-class peptide TT-P34 was safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease, with pharmacokinetic data showing dose-dependent central nervous system exposure and early biomarker signals consistent with lysosomal pathway modulation.

Phase 1 supports progression into Parkinson’s disease

Teitur Trophics reported positive Phase 1 results for TT-P34, supporting plans to advance the peptide into a Phase 2 study in Parkinson’s disease in 2027. The early-stage trial evaluated safety, tolerability, pharmacokinetics and mechanism-related biomarkers in healthy volunteers and patients with early-stage disease.

The findings are particularly relevant to Parkinson’s disease, where current treatments primarily control symptoms rather than modify the underlying neurodegenerative process. More than 10 million people worldwide live with the disease, according to the company.

Dual targeting of mitochondrial and lysosomal function

TT-P34 is being developed as a neuroprotective peptide that acts through a dual mechanism to improve mitochondrial and lysosomal function. Dysfunction in both systems contributes to neuronal stress and degeneration in Parkinson’s disease and other neurodegenerative disorders.

The program also has potential applications in frontotemporal dementia and Huntington’s disease, although clinical development has so far focused on Parkinson’s disease.

Weekly dosing produced robust CNS exposure

The randomized, double-blind, placebo-controlled Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands.

The study enrolled 55 healthy volunteers, including 31 participants in the single ascending dose portion and 24 in the multiple ascending dose portion. A further cohort included 12 patients with early-stage Parkinson’s disease.

Once-weekly subcutaneous TT-P34 was safe and well tolerated across all tested doses, with no dose-limiting findings. The peptide also showed an acceptable safety profile when administered alongside standard Parkinson’s treatment with levodopa.

Pharmacokinetic analyses confirmed that TT-P34 crosses the blood-brain barrier, producing robust, dose-dependent exposure in the brain and central nervous system. The exposure profile also supported once-weekly administration.

CSF biomarkers indicate pathway engagement

The trial generated a panel of mechanism-related biomarkers measurable in cerebrospinal fluid (CSF), allowing investigators to assess whether TT-P34 was affecting its intended biological pathway.

During the 50-day study, investigators observed clear trends in biomarker movement. Most Parkinson’s patients who received TT-P34 showed coordinated changes across multiple lysosomal proteins in CSF.

Because these proteins can be measured directly in CSF, the coherent signal provides early evidence of lysosomal pathway modulation. Teitur said the findings are consistent with its proposed mechanism for restoring both lysosomal and mitochondrial function.

Andreas Borta, chief medical officer of Teitur Trophics, highlighted the combination of safety, pharmacokinetic exposure and biomarker findings as the key outcome from the study.

Phase 2 planned for 2027

The company is now preparing for a Phase 2 Parkinson’s trial expected to begin in 2027, with the next study expected to investigate the potential therapeutic and disease-modifying effects of TT-P34 in patients.

The Phase 1 findings will be presented at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea, on October 5. The presentation is scheduled for 9:30–9:40 a.m. at E-Poster Hall D, Station 12.

Teitur is also raising a Series B financing round to support the next stage of clinical development.

Reference

Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34, Teitur Trophics, 10 September 2026